GSK (GSK) Short Interest Ratio & Short Volume $34.23 +0.65 (+1.94%) (As of 12/17/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GSK Short Interest DataGSK (GSK) has a short interest of 19.35 million shares, representing 0.95% of the float (the number of shares available for trading by the public). This marks a -17.73% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.4, indicating that it would take 3.4 days of the average trading volume of 4.16 million shares to cover all short positions.Current Short Interest19,350,000 sharesPrevious Short Interest23,520,000 sharesChange Vs. Previous Month-17.73%Dollar Volume Sold Short$660.42 millionShort Interest Ratio3.4 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares2,072,550,000 sharesFloat Size2,040,000,000 sharesShort Percent of Float0.95%Today's Trading Volume4,546,212 sharesAverage Trading Volume4,163,735 sharesToday's Volume Vs. Average109% Short Selling GSK? Sign up to receive the latest short interest report for GSK and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGSK Short Interest Over TimeGSK Days to Cover Over TimeGSK Percentage of Float Shorted Over Time Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol GSK Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202419,350,000 shares $660.42 million -17.7%1.0%3.4 $34.13 11/15/202423,520,000 shares $784.27 million +44.4%1.2%4.1 $33.35 10/31/202416,290,000 shares $598.49 million -1.6%0.8%3.3 $36.74 10/15/202416,550,000 shares $644.79 million +59.8%0.8%3.9 $38.96 9/30/202410,360,000 shares $423.52 million -11.4%0.5%2.7 $40.88 9/15/202411,690,000 shares $502.79 million +7.2%0.6%3.2 $43.01 Get the Latest News and Ratings for GSK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. 8/31/202410,910,000 shares $479.06 million +13.1%0.5%3.2 $43.91 8/15/20249,650,000 shares $399.41 million -21.4%0.5%2.7 $41.39 7/31/202412,270,000 shares $475.89 million -11.3%0.6%3.3 $38.79 7/15/202413,840,000 shares $535.33 million +4.7%0.7%3.9 $38.68 6/30/202413,220,000 shares $508.97 million +57.4%0.7%3.6 $38.50 6/15/20248,400,000 shares $341.46 million +5.8%0.4%2.3 $40.65 5/31/20247,940,000 shares $355.47 million -25.0%0.4%2.4 $44.77 5/15/202410,590,000 shares $484.07 million +17.8%0.5%3.3 $45.71 4/30/20248,990,000 shares $372.46 million +22.3%0.4%2.7 $41.43 4/15/20247,350,000 shares $297.68 million +52.2%0.4%2.1 $40.50 3/31/20244,830,000 shares $207.06 million +21.7%0.2%1.4 $42.87 3/15/20243,970,000 shares $167.49 million -16.6%0.2%1.1 $42.19 2/29/20244,760,000 shares $199.40 million +3.0%0.2%1.3 $41.89 2/15/20244,620,000 shares $193.02 million +40.4%0.2%1.3 $41.78 1/31/20243,290,000 shares $129.74 million +18.4%0.2%1 $39.44 1/15/20242,780,000 shares $111.48 million +1.5%0.1%0.9 $40.10 12/31/20232,740,000 shares $101.54 million -6.2%0.1%0.9 $37.06 12/15/20232,920,000 shares $104.76 million +5.4%0.1%0.9 $35.88 11/30/20232,770,000 shares $99.71 million -25.9%0.1%0.8 $36.00 11/15/20233,740,000 shares $128.92 million -6.5%0.2%1 $34.47 10/31/20234,000,000 shares $142.80 million -17.4%0.2%1.1 $35.70 10/15/20234,840,000 shares $177.53 million -8.2%0.2%1.4 $36.68 9/30/20235,270,000 shares $191.04 million -5.4%0.3%1.6 $36.25 9/15/20235,570,000 shares $208.46 million +14.9%0.3%1.7 $37.43 8/31/20234,850,000 shares $170.48 million -7.8%0.2%1.4 $35.15 8/15/20235,260,000 shares $185.47 million +6.1%0.3%1.6 $35.26 7/31/20234,960,000 shares $176.43 million +1.6%0.2%1.6 $35.57 7/15/20234,880,000 shares $168.51 million +3.8%0.2%1.6 $34.53 6/30/20234,700,000 shares $167.51 million +22.4%0.2%1.5 $35.64 6/15/20233,840,000 shares $135.44 million +15.3%0.2%1.3 $35.27 5/31/20233,330,000 shares $111.89 million -10.5%0.2%1.2 $33.60 5/15/20233,720,000 shares $136.82 million -5.8%0.2%1.3 $36.78 4/30/20233,950,000 shares $142.32 million +16.2%0.2%1.2 $36.03 4/15/20233,400,000 shares $128.42 million +4.0%0.2%1 $37.77Healthcare Takes A Big Step Forward With The Help of A.I. (Ad)To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the 3/31/20233,270,000 shares $116.35 million -14.8%0.2%0.9 $35.58 3/15/20233,840,000 shares $128.95 million +33.3%0.2%1 $33.58 2/28/20232,880,000 shares $98.70 million -23.0%0.1%0.6 $34.27 2/15/20233,740,000 shares $133.03 million -50.5%0.2%0.8 $35.57 1/31/20237,550,000 shares $266.21 million +0.7%0.4%1.5 $35.26 1/15/20237,500,000 shares $265.35 million -11.0%0.4%1.4 $35.38 12/30/20228,430,000 shares $296.23 million -22.8%0.4%1.5 $35.14 12/15/202210,920,000 shares $389.08 million -5.3%0.5%1.7 $35.63 11/30/202211,530,000 shares $398.82 million +2.5%0.6%1.7 $34.59 11/15/202211,250,000 shares $363.26 million -15.8%0.6%1.8 $32.29 10/31/202213,360,000 shares $443.15 million -15.8%0.7%1.8 $33.17 10/15/202215,870,000 shares $487.37 million +0.3%0.8%2.3 $30.71 9/30/202215,830,000 shares $465.88 million +13.3%0.8%2.3 $29.43 9/15/202213,970,000 shares $433.35 million +10.0%0.7%2.2 $31.02 8/31/202212,700,000 shares $412.50 million +49.1%0.6%2.1 $32.48 8/15/20228,520,000 shares $297.77 million +39.2%0.4%1.5 $34.95 7/31/20226,120,000 shares $258.08 million +9.9%0.3%1.3 $42.17 7/15/20225,570,000 shares $229.76 million -16.7%0.3%1.2 $41.25 6/30/20228,360,000 shares $363.91 million -6.0%N/A1.5 $43.53 6/15/20228,890,000 shares $372.94 million +74.7%N/A1.6 $41.95 5/31/20225,090,000 shares $223.45 million -15.5%0.2%0.9 $43.90 5/15/20226,020,000 shares $260.79 million -18.1%0.2%1.1 $43.32 4/30/20227,350,000 shares $332.81 million +10.4%0.3%1.5 $45.28 4/15/20226,660,000 shares $308.49 million +1.7%0.3%1.3 $46.32 3/31/20226,550,000 shares $285.32 million -12.4%0.3%1.3 $43.56 3/15/20227,480,000 shares $311.92 million +8.4%0.3%1.6 $41.70 2/28/20226,900,000 shares $288.83 million -15.7%0.3%1.5 $41.86 2/15/20228,180,000 shares $356.81 million +1.6%0.3%1.9 $43.62 1/31/20228,050,000 shares $360.80 million -15.5%0.3%2 $44.82 1/15/20229,530,000 shares $433.33 million -11.4%0.4%2.2 $45.47 12/31/202110,750,000 shares $474.08 million +3.3%0.5%2.6 $44.10 12/15/202110,410,000 shares $454.50 million -10.9%0.5%2.4 $43.66 11/30/202111,680,000 shares $480.28 million -5.3%0.5%2.7 $41.12 11/15/202112,330,000 shares $532.29 million -20.9%0.5%3 $43.17 10/29/202115,580,000 shares $659.50 million -7.1%0.6%3.9 $42.33 10/15/202116,770,000 shares $654.20 million -4.6%0.7%4.5 $39.01 9/30/202117,570,000 shares $671.35 million +7.6%0.7%4.8 $38.21 9/15/202116,330,000 shares $640.46 million -0.7%0.7%4.4 $39.22 8/31/202116,440,000 shares $669.77 million +2.8%0.7%4.2 $40.74 8/13/202115,990,000 shares $671.10 million +6.3%0.6%3.9 $41.97 7/30/202115,040,000 shares $603.71 million -1.6%0.6%3.5 $40.14 7/15/202115,290,000 shares $605.79 million +5.8%0.6%3.6 $39.62 6/30/202114,450,000 shares $575.40 million -22.4%0.6%3.2 $39.82 6/15/202118,630,000 shares $755.82 million -8.9%0.8%3.9 $40.57 5/28/202120,460,000 shares $793.23 million -13.3%0.8%4.4 $38.77 5/14/202123,600,000 shares $912.38 million -5.3%N/A4.6 $38.66 4/30/202124,920,000 shares $934.50 million -11.6%N/A4.4 $37.50 4/15/202128,200,000 shares $1.02 billion +1.9%N/A4.4 $36.13 3/31/202127,670,000 shares $1.01 billion +17.6%N/A4.6 $36.37 3/15/202123,520,000 shares $835.90 million +14.7%N/A4.1 $35.54Healthcare Takes A Big Step Forward With The Help of A.I. (Ad)To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the 2/26/202120,500,000 shares $704.79 million +5.6%N/A3.6 $34.38 2/12/202119,410,000 shares $685.56 million +37.1%N/A3.6 $35.32 1/29/202114,160,000 shares $538.50 million +3.1%N/A2.7 $38.03 1/15/202113,730,000 shares $523.94 million +5.1%N/A2.8 $38.16 12/31/202013,060,000 shares $483.74 million +8.7%N/A2.6 $37.04 12/15/202012,010,000 shares $442.33 million +6.5%N/A2.5 $36.83 11/30/202011,280,000 shares $418.15 million -18.3%N/A2.4 $37.07 11/15/202013,800,000 shares $528.54 million +29.1%N/A3.1 $38.30 10/30/202010,690,000 shares $363.03 million -5.7%N/A2.8 $33.96 10/15/202011,340,000 shares $421.96 million +2.4%N/A3.4 $37.21 9/30/202011,080,000 shares $417.05 million -2.7%N/A3.6 $37.64 9/15/202011,390,000 shares $447.29 million +14.1%N/A4 $39.27 8/31/20209,980,000 shares $395.21 million +1.6%N/A3.4 $39.60 8/14/20209,820,000 shares $398.20 million -5.2%N/A3.3 $40.55 7/31/202010,360,000 shares $417.72 million +2.5%N/A3.3 $40.32 7/15/202010,110,000 shares $424.11 million +6.0%N/A3.2 $41.95 6/30/20209,540,000 shares $389.14 million +19.1%N/A2.9 $40.79 6/15/20208,010,000 shares $326.17 million -7.4%N/A2.1 $40.72 5/29/20208,650,000 shares $362.61 million -22.8%N/A1.9 $41.92 5/15/202011,200,000 shares $458.19 million +11.3%N/A2.2 $40.91 4/30/202010,060,000 shares $423.22 million +5.5%N/A1.9 $42.07 4/15/20209,540,000 shares $379.88 million -5.0%N/A1.8 $39.82 3/31/202010,040,000 shares $426.70 million +13.5%N/A2 $42.50 3/13/20208,846,000 shares $343.93 million +70.4%N/A2.5 $38.88 2/28/20205,190,000 shares $165.30 million -5.3%N/A1.4 $31.85 2/14/20205,480,000 shares $224.79 million -29.4%N/A1.8 $41.02 1/31/20207,760,000 shares $325.14 million +16.7%0.3%2.8 $41.90 1/15/20206,650,000 shares $295.39 million -8.5%0.3%2.4 $44.42 12/31/20197,270,000 shares $343.36 million +2.3%0.3%2.8 $47.23 GSK Short Interest - Frequently Asked Questions What is GSK's current short interest? Short interest is the volume of GSK shares that have been sold short but have not yet been closed out or covered. As of November 30th, traders have sold 19,350,000 shares of GSK short. 0.95% of GSK's shares are currently sold short. Learn More on GSK's current short interest. What is a good short interest ratio for GSK? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GSK shares currently have a short interest ratio of 3.0. Learn More on GSK's short interest ratio. Which institutional investors are shorting GSK? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of GSK: Jane Street Group LLC, Wolverine Trading LLC, Parallax Volatility Advisers L.P., Verition Fund Management LLC, Walleye Trading LLC, Walleye Capital LLC, Genus Capital Management Inc., IMC Chicago LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for GSK? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.95% of GSK's floating shares are currently sold short. Is GSK's short interest increasing or decreasing? GSK saw a drop in short interest during the month of November. As of November 30th, there was short interest totaling 19,350,000 shares, a drop of 17.7% from the previous total of 23,520,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is GSK's float size? GSK currently has issued a total of 2,072,550,000 shares. Some of GSK's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. GSK currently has a public float of 2,040,000,000 shares. How does GSK's short interest compare to its competitors? 0.95% of GSK's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to GSK: AstraZeneca PLC (0.24%), Novartis AG (0.23%), Sanofi (0.18%), Takeda Pharmaceutical Company Limited (0.15%), BioNTech SE (0.99%), Teva Pharmaceutical Industries Limited (1.98%), BeiGene, Ltd. (1.37%), Moderna, Inc. (11.90%), Viatris Inc. (1.78%), Summit Therapeutics Inc. (2.28%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short GSK stock? Short selling GSK is an investing strategy that aims to generate trading profit from GSK as its price is falling. GSK shares are trading up $0.65 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against GSK? A short squeeze for GSK occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GSK, which in turn drives the price of the stock up even further. How often is GSK's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GSK, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies AstraZeneca Short Squeeze Novartis Short Squeeze Sanofi Short Squeeze Takeda Pharmaceutical Short Squeeze BioNTech Short Squeeze Teva Pharmaceutical Industries Short Squeeze BeiGene Short Squeeze Moderna Short Squeeze Viatris Short Squeeze Summit Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:GSK) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
